Our science
Evidence is theonly aesthetic wewon't compromise.
ObNowa's development philosophy is simple to state and demanding to practice: molecular integrity first, clinical evidence second, commercial narrative last.
Development approach
Rigorous science.
Meaningful evidence.
Disciplined development.
Scientific rationale
Clear scientific rationale before development.
Meaningful endpoints
Clinically relevant and measurable outcomes.
Global standards
Development designed to meet global and EU standards.
Scientific domains
Two areas of science, one standard of proof.
ObNowa rights — Europe
Follicle biology & growth-cycle modulation
Through its European licence to hair-growth programs originating from Aneira Pharma, ObNowa is developing scalp and eyebrow programs for the European market. The portfolio is built around mechanisms involved in follicular signalling and hair-growth cycle regulation, with development tailored to the biology and clinically relevant endpoints of each intended use.
Geographic strategy — Global
Precision aesthetic neuromodulation
ObNowa's neurotoxin programs build on science originating from Object Pharma and are developed to global regulatory standards. The portfolio comprises a bio-comparable program designed around established performance standards and a bio-better program exploring differentiated neurotoxin characteristics.
Methodology
How candidates earn their stage.
Programs advance only when the evidence supports progression to the next stage. Our development approach follows established principles of pharmaceutical development, adapted to the specific requirements of aesthetic medicine.
In-vitro characterisation and mechanism confirmation
Preclinical safety, tolerability and formulation development
Staged clinical evaluation under EU regulatory frameworks
Analytical comparability programs for reference-based candidates
Peer-reviewed publication and data sharing as programs mature
Development status — all programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.